OncoMatch/Clinical Trials/NCT07003074
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Is NCT07003074 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including TQB2102 for and Docetaxel combined + Trastuzumab +Pertuzumab for breast cancer.
Treatment: TQB2102 for · Docetaxel combined + Trastuzumab +Pertuzumab — This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) positive
HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: consisting of topoisomerase I inhibitors
Previously received antibody conjugate therapy consisting of topoisomerase I inhibitors
Cannot have received: radiation therapy
Received radiation therapy within 3 weeks prior to the start of study treatment
Cannot have received: endocrine therapy
endocrine therapy within 2 weeks prior to the start of study treatment
Cannot have received: traditional Chinese patent medicines and simple preparations with anti-tumor indications
Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment
Cannot have received: anthracycline
History of cumulative dose exposure to anthracyclines in the past
Cannot have received: anti-tumor therapy (clinical trial participation)
Participated in other clinical trials of anti-tumor therapy within 4 weeks before the start of the research treatment
Lab requirements
Blood counts
Good major organ function
Kidney function
Good major organ function
Liver function
Good major organ function
Good major organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify